Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
A recent study by Xiong Yu-Ting and colleagues has unveiled the clinical characteristics and risk factors of acute drug-induced liver injury (DILI). Upon reading the article, we found that there are some differences between female and male patients with DILI in terms of clinical and pathological features, especially in the number of patients, the degree of liver inflammation, and the risk of autoimmune liver disease. Therefore, it is necessary to pay attention to female patients with DILI and their outcomes, and to intervene appropriately in advance. This article analyzes the reasons for the differences between female and male patients with DILI and makes recommendations for patient prognosis.
Xiong YT, Wang JF, Li L, et al. Risk factors related to significant hepatic inflammation in patients with acute drug-induced liver injury. iLIVER 2024;3(2): 100095. https://doi.org/10.1016/j.iliver.2024.100095.
Andrade RJ, Aithal GP, de Boer YS, et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH):an expert opinion meeting report. J Hepatol 2023;79(3):853–66. https://doi.org/10.1016/j.jhep.2023.04.033.
Xiong YT, Wang JF, Niu XX, et al. Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury. Front Pharmacol 2023;14: 1071709. https://doi.org/10.3389/fphar.2023.1071709.
Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41(7):816–9. https://doi.org/10.1038/ng.379.
Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ 2020;11(1):32. https://doi.org/10.1186/s13293-020-00308-5.
Mao Y, Ma S, Liu C, et al. Chinese guideline for the diagnosis and treatment of druginduced liver injury: an update. Hepatol Int 2024;18(2):384–419. https://doi.org/10.1007/s12072-023-10633-7.
Sarwar R, Pierce N, Koppe S. Obesity and nonalcoholic fatty liver disease: current perspectives. Diabetes Metab Syndr Obes 2018;11:533–42. https://doi.org/10.2147/DMSO.S146339.
Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011;56(4):958–76. https://doi.org/10.1007/s10620-011-1611-4.
Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 2015;17(1):14. https://doi.org/10.3390/ijms17010014.
García-Cortés M, Ortega-Alonso A, Matilla-Cabello G, et al. Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries. Liver Int 2023;43(8):1749–60. https://doi.org/10.1111/liv.15623.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).